BridgeMD
Tests treatment safety and results for Cognitive Remediation
Official title Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy
ClinicalTrials.gov ID: NCT05667857
What this study is testing
- What it's testing
- Since 2010, the field of immunotherapy has grown substantially, leading to a growing population of long-term cancer survivors treated with immunotherapy. Since cancer survivorship in immunotherapy is an emerging field, to date not much is known about psychosocial and neurocognitive survivorship-related issues in advanced cancer survivors treated with immunotherapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Non-intervention group:
- Provision of written informed consent
- Diagnosed with advanced cancer of any type
- Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago
- Have a confirmed normalization on whole-body 18F-FDG PET
You likely can't join if
- severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with...
See the full eligibility criteria
- Non-intervention group:
- Provision of written informed consent
- Diagnosed with advanced cancer of any type
- Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago
- Have a confirmed normalization on whole-body 18F-FDG PET
- English, Dutch or French-speaking
- Integrative neurocognitive remediation therapy group:
- Provision of written informed consent
- Objective cognitive impairment and/or subjective cognitive complaints
- Confirmed normalization on whole-body 18F-FDG PET for patients (cohort 1)
- Disease-free (cohort 2) or no active disease for patients with CNS tumors (cohort 3)
- Having received a cancer therapy of any kind
- Having ended cancer treatment (immunotherapy, chemotherapy, radiotherapy, surgery, …) with an exception of ongoing adjuvant hormone therapy
- Dutch or French speaking
- severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are...
The study team makes the final eligibility decision.
Where it's taking place
- Brussels, Brussels Capital, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brussels, Brussels Capital, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.